QWay Health brings to you the news stories that are making headlines in the medical industry this week. Go through our short and concise news article to quickly get a note of what is happening around you.
- As the USA braces itself for the 3rd wave of the pandemic, the Government is most likely to roll out a booster dose plan for the vaccinated population.
- People who received both doses of the Covid-19 vaccines from Moderna or Pfizer will be eligible for the booster shot.
- In the case of Johnson and Johnson, the Government is awaiting its reports for a second dose.
- According to the sources, the vaccinated population is need for a booster dose to fight effectively against the evolved variants of the Covid-19 virus.
- The booster shots however have not been approved by FDA yet, though the Government sources say that the roll-out might begin as early as September.
- Earlier this week, FDA had approved the booster doses for all immune- compromised people in the USA. This move has a strong support from the CDC.
- FDA has approved the drug Xywav, produced by Jazz Pharmaceuticals, to treat a rare sleeping condition called Idiopathic Hypersomnia.
- The drug had previously been highly regulated in the market due to its possible rippling addiction effects.
- The FDA approval has caused controversies among scientists and medical experts who have mixed reactions about the drug.
- The experts pointed out the dearth of solid evidence on the efficacy of the drug.
- On the other hand, there is substantial proof to show that the drug has multiple side-effects like anxiety and depression.
- Idiopathic Hypersomnia is a condition where people feel tired even after sleeping for more than nine or ten hours a day.
- The recently launched Philips HealthSuite is expected to bring a positive change in patient treatment and clinical outcomes.
- This health informatics tool can analyze the patient information and provide results with precision.
- The end-to-end care program of a patient can be tracked and improved with the help of Philips’ Patient Flow Capacity Suite.
- Philips’ Acute Care Telehealth model is considered to be a significant leap in the field of combining critical health with telemedicine, with the help of a central or decentralized command system.
- In the upcoming projects, Philips will venture into anesthesia, acute care and EHRs.
- Houston-based University of Texas Health Science Center has signed an agreement with health technology firm Holmusk, to provide real patient data to help develop AI models.
- The health information of the patients will be deidentified prior to sharing.
- With this deal, Holmusk will get access to around 80,000 health records in a year from the UTHealth and The Harris Center for Mental Health and IDD.
- The AI models are aimed at improving the statistical approach to patient care and clinical outcomes.
- They will analyze the data to predict the frequency of a patient’s need for hospitalization or visit to a clinic.
- Real patient data will significantly boost the efficacy of the system.
- Anthem and Dignity Health has reached a multi-year contract yet again, which came into retrospective effect from July 15th.
- This comes as a relief for many healthcare providers as well as patients who had suffered from the contract expiration.
- The announcement says that any services that have taken place after the previous contract expired can be billed as an “in-network” service.
- This comes as a welcoming call for all patients who had sought care from any other organizations and wish to return to Dignity.
- 30 hospitals of Dignity Heath had suffered during the one month when the contract expiration was in effect. With the press release, the organizations can return to usual business.
- Pharmacies and hospitals are still at loggerheads with respect to the 340B discounts, with Merck being the most recent pharmacy to impose a condition.
- According to Merck and many other drug maker giants, the hospitals need to provide the claims data in order to get the 340B discount.
- In case the hospitals do not have their in-house pharmacy, then they need to designate a single-contract one to receive the discounts.
- This has been done to prevent double discounts from both Medicaid and 340B from the hospitals. However, not many hospitals have agreed on these terms.
- The formal legal battle is yet to begin, with several cases piled up in the courts.
- There is still a lot of doubt whether the pharmacies have an authority to withdraw the discounts for 340B eligible hospitals.
- In a recent announcement, the Centers for Medicare and Medicaid have decided to give more time to states to determine their Medicaid enrollment eligibility.
- The new rule now mandates the states to prepare their enrollment eligibility 6 months prior to the conclusion of the public health emergency.
- However, many states have spoken out on this new rule since there is no predetermined date for the public health emergency to conclude as of yet.
- They fear a significant increase in administrative burden due to the sudden date timeline.
- According to a lot of states, spreading out the renewal process throughout the year is more effective in maintaining the administration.
- The number of enrollees in Medicaid and the Children’s Health Insurance Program is at an all-time high with over 81 Million applications.
- The CMS has published its strategy plan for the upcoming 10 years after carefully evaluating the existing models in place.
- Payment models have featured in the highlights since only 6 out of 50 managed to help in savings for Medicare and taxpayers.
- They were also thought to be complicated for the process with a lower success rate. In the coming decade, CMS will focus on improving the success rate of the existing models and introduce lesser ones.
- CMS has also categorized voluntary models as financially less lucrative, with lesser potentials of saving.
- The federal body is also focused on bridging the data gap between Medicare and Medicaid plans and innovation centers.
For more such interesting blogs, articles and news, please subscribe to our blog. Follow us on Facebook, Instagram, Twitter and LinkedIn to get regular updates.